Victor Bui, PA
Physician Assistant · Pearland, TXNPI 1871187443
Payments from drug & device makers
Across 1,082 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $9K from 27 others
What the payments were for
- Food & beverage$20,084100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 74 | $2,454 |
| Otsuka America Pharmaceutical, Inc. | 98 | $2,171 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 112 | $1,606 |
| AbbVie | 98 | $1,579 |
| Alkermes, Inc. | 81 | $1,548 |
| Teva Pharmaceuticals USA, Inc. | 78 | $1,535 |
| Johnson & Johnson | 71 | $1,116 |
| Vanda Pharmaceuticals Inc. | 42 | $1,044 |
| Supernus Pharmaceuticals, Inc. | 68 | $915 |
| Lundbeck LLC | 53 | $912 |
| Axsome Therapeutics, Inc. | 34 | $855 |
| Corium, LLC | 56 | $848 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $679 |
| Tris Pharma Inc | 19 | $448 |
| E.r. Squibb & Sons, L.L.C. | 25 | $432 |
| Sunovion Pharmaceuticals Inc. | 43 | $350 |
| Indivior Inc. | 16 | $325 |
| Ironshore Pharmaceuticals Inc. | 17 | $321 |
| Neos Therapeutics, LP | 14 | $200 |
| Tempus AI, Inc | 8 | $178 |
| OWP Pharmaceuticals, Inc. | 4 | $81 |
| Acadia Pharmaceuticals Inc | 4 | $81 |
| Idorsia Pharmaceuticals US Inc | 5 | $77 |
| Eisai Inc. | 4 | $73 |
| Luye Pharma (USA) Ltd. | 2 | $45 |
| Noven Therapeutics, LLC | 2 | $41 |
| Boston Scientific | 1 | $40 |
| Validus Pharmaceuticals LLC | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Bausch Health US, LLC | 1 | $24 |
| Sage Therapeutics, LLC | 1 | $24 |
| Almatica Pharma LLC | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,425
- INGREZZA$905
- ARISTADA$500
- REXULTI$250
- Fanapt$250
- VRAYLAR$230
- INVEGA SUSTENNA$230
- AUSTEDO$220
- ARISTADA INITIO$125
- Quillichew ER$125
- Quillivant$125
- Dyanavel XR$125
- CAPLYTA$121
- ABILIFY MYCITE$116
How this compares
$20,085 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $187,524 |
| VraylarCariprazine Hcl | 43 | $73,752 |
| Invega SustennaPaliperidone Palmitate | 24 | $55,279 |
| CaplytaLumateperone Tosylate | 12 | $36,947 |
| RexultiBrexpiprazole | 12 | $20,009 |
| Lurasidone Hcl | 31 | $12,033 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $11,132 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $4,763 |
| Modafinil | 11 | $2,826 |
| Fluoxetine DrFluoxetine Hcl | 16 | $2,735 |
| Quetiapine Fumarate | 52 | $1,505 |
| Risperidone | 22 | $1,130 |
| Bupropion XlBupropion Hcl | 16 | $1,126 |
| Hydroxyzine Hcl | 33 | $899 |
| Aripiprazole | 28 | $861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,454 | $187,52422 claims |
| AbbVieVraylar | $1,579 | $73,75243 claims |
| Johnson & JohnsonInvega Sustenna | $1,116 | $55,27924 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,606 | $36,94712 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,171 | $20,00912 claims |
| Axsome Therapeutics, Inc.Auvelity | $855 | $11,13217 claims |
| Almatica Pharma LLCSertraline Hcl | $21 | $60948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Pearland
- Shauna McLaughlinPearland$37K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.